Table 2.
Short-term relative conditional survival (%) based on varying conditioning points with 95% confidence intervals for all primary brain tumors: 1985–2005
| 6-mo CS upon 0.5 year | 6-mo CS upon 1 year | 1-year CS upon 1 year | 6-mo CS upon 1.5 years | 1-year CS upon 2 years | |
|---|---|---|---|---|---|
| Years since diagnosis | 1 year | 1.5 years | 2 years | 2 years | 3 years |
| All brain tumors | 85.7 (84.9–86.5) | 90.6 (89.5–91.5) | 85.8 (84.6–86.9) | 94.7 (93.5–95.7) | 94.4 (92.9–95.6) |
| Tumor behavior | |||||
| Malignant | 74.9 (73.7–76.1) | 80.9 (79.2–82.4) | 71.6 (69.6–73.4) | 88.4 (86.3–90.2) | 87.8 (85.0–90.1) |
| Nonmalignant | 98.7 (97.9–99.2) | 99.5 (98.0–99.9) | 99.0 (97.7–99.6) | 99.5 (97.8–99.9) | 99.0 (97.5–99.7) |
| Specified histologic subtypes | |||||
| Primarily malignant | |||||
| Diffuse astrocytoma | 83.3 (78.3–87.2) | 84.7 (76.8–90.1) | 78.2 (67.7–85.6) | 92.2 (78.6–97.3) | 86.7 (70.5–94.4) |
| Anaplastic astrocytoma | 79.8 (76.5–82.7) | 84.6 (79.4–88.6) | 72.1 (65.3–77.8) | 85.1 (78.3–89.9) | 82.8 (72.6–89.4) |
| Glioblastoma | 52.9 (51.2–54.6) | 52.1 (49.2–55.0) | 30.9 (27.6–34.2) | 59.1 (54.3–63.6) | 56.0 (48.1–63.1) |
| Oligodendroglioma | 97.3 (95.8–98.3) | 96.7 (94.3–98.1) | 95.3 (91.9–97.3) | 98.6 (93.8–99.7) | 94.8 (90.5–97.1) |
| Anaplastic oligodendroglioma | 89.6 (84.0–93.4) | 90.7 (81.5–95.5) | 80.0 (67.6–88.1) | 88.2 (76.3–94.3) | 91.3 (65.6–98.1) |
| Mixed glioma | 92.0 (88.0–94.7) | 92.3 (85.9–95.9) | 84.2 (75.2–90.2) | 91.3 (82.8–95.7) | 90.2 (76.3–96.1) |
| Astrocytoma (NOS) | 82.0 (79.8–84.0) | 88.0 (84.7–90.7) | 82.2 (77.9–85.7) | 93.3 (88.7–96.1) | 91.1 (85.0–94.8) |
| Glioma, malignant (NOS) | 78.6 (74.9–81.8) | 84.8 (78.9–89.1) | 78.3 (70.8–84.1) | 92.3 (83.1–96.6) | 92.1 (78.1–97.3) |
| Embryonal/primitive medulloblastoma | 89.5 (86.5–91.9) | 92.2 (87.4–95.2) | 89.4 (83.2–93.4) | 97.0 (87.7–99.3) | 93.3 (84.4–97.2) |
| Lymphoma | 77.3 (73.3–80.7) | 83.8 (77.5–88.6) | 75.0 (66.8–81.5) | 89.4 (80.1–94.5) | 82.4 (70.4–89.9) |
| Meningioma, malignant | 94.9 (90.1–97.4) | 95.4 (87.0–98.4) | 92.7 (81.2–97.3) | 97.1 (80.2–99.6) | 92.7 (77.9–97.7) |
| Neoplasm, unspecified | 80.6 (75.3–84.9) | 89.5 (80.2–94.6) | 83.1 (71.7–90.3) | 92.8 (78.6–97.7) | 89.2 (71.6–96.1) |
| Ependymoma | 98.1 (96.2–99.0) | 97.4 (94.4–98.7) | 95.4 (91.1–97.7) | 98.0 (93.3–99.4) | 95.1 (89.5–97.7) |
| Germ cell tumor | 99.4 (95.5–99.9) | 96.8 (91.8–98.8) | 94.2 (85.6–97.7) | 97.3 (88.3–99.4) | 99.3 (0–100) |
| Primarily nonmalignant | |||||
| Pilocytic astrocytoma | 99.0 (97.8–99.5) | 99.7 (92.0–100) | 99.3 (95.8–99.9) | 99.5 (95.3–100) | 99.2 (94.7 99.9) |
| Hemangioblastoma/hemangioma | 98.8 (95.5–99.7) | 99.4 (79.1–100) | 99.4 (62.1–100) | 100a | 99.0 (79.9–100) |
| Craniopharyngioma | 99.4 (92.1–100) | 96.9 (90.3–99.0) | 95.7 (83.7–98.9) | 98.6 (71.9–99.9) | 99.7 (0–100) |
| Meningioma, nonmalignant | 98.4 (97.8–98.8) | 99.4 (98.2–99.8) | 98.8 (97.3–99.5) | 99.4 (97.8–99.8) | 98.9 (96.8–99.6) |
| Nerve sheath and other cranial/spinal nerve tumor | 99.9 (85.7–100) | 99.6 (97.3–100) | 99.3 (95.7–99.9) | 99.6 (96.1–100) | 99.7 (81.9–100) |
| Pituitary tumor | 99.5 (98.7–99.8) | 99.8 (92.8–100) | 99.4 (96.2–99.9) | 99.6 (96.8–100) | 99.4 (94.7–99.9) |
| Neuronal/glial, nonmalignant and malignant | 95.2 (91.4–97.3) | 4.7 (88.7–97.6) | 93.0 (84.6–96.9) | 98.2 (78.8–99.9) | 98.6 (30.2–100) |
| All other brain tumors | 93.1 (89.4–95.5) | 95.0 (88.8–97.8) | 91.9 (83.8–96.0) | 96.7 (86.3–99.2) | 95.3 (81.4–98.9) |
a Confidence interval undefined.
CS = Conditional survival; NOS = not otherwise specified.